Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medication is generally administered once daily with the evening meal.
The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior experience with antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy alone:
When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions to metformin.
In patients switching from combination therapy with dapagliflozin and metformin to this medication, the dose may be initiated at the existing doses of dapagliflozin and metformin. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate.
The safety and efficacy of this medication have not been specifically evaluated in patients switching from other glucose-lowering agents. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring.
This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is necessary in patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher but less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medication is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medication should be discontinued immediately. Renal function should be assessed every 3~6 months.
Elderly patients
Because metformin is excreted through the kidneys and renal function tends to decline in elderly patients, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
Improvement of glycemic control in adults with type 2 diabetes
View approved original textHide original text
This medication is used as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes by administering a combination of dapagliflozin and metformin. Particularly in patients whose glycemic control is insufficient, it is important to refer to expert guidance on the cardiovascular effects of dapagliflozin if there are cardiovascular diseases or risk factors present. This medication effectively helps with blood sugar control and positively supports diabetes management.
How to take
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medication is generally administered once daily with the evening meal.
The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior experience with antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy alone:
When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions to metformin.
In patients switching from combination therapy with dapagliflozin and metformin to this medication, the dose may be initiated at the existing doses of dapagliflozin and metformin. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate.
The safety and efficacy of this medication have not been specifically evaluated in patients switching from other glucose-lowering agents. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring.
This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is necessary in patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher but less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medication is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medication should be discontinued immediately. Renal function should be assessed every 3~6 months.
Elderly patients
Because metformin is excreted through the kidneys and renal function tends to decline in elderly patients, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
Precautions
This medication is used in the treatment of type 2 diabetes and contains two components.
First, the metformin component helps lower blood sugar, but can rarely cause a serious side effect called lactic acidosis. Lactic acidosis is a dangerous condition resulting from an excessive buildup of lactic acid in the body, with symptoms including muscle pain, shortness of breath, weakness, and abdominal pain. If such symptoms occur, consult a physician immediately.
Additionally, caution is needed as this medication may pose a risk of hypoglycemia when used with insulin or sulfonylureas. Hypoglycemia can cause symptoms such as dizziness, trembling, and cold sweats.
This medication should not be used in patients with poor kidney function, those who are dehydrated, with serious infections, cardiac dysfunction, pregnant or breastfeeding women, and those with certain genetic disorders. In particular, patients with severely impaired kidney function are at risk if they take this medication.
Regular kidney function tests are important before and during treatment to check for abnormalities, and elderly patients or those with reduced fluid volume require closer management.
This medication can increase urination, potentially leading to reduced fluid volume or low blood pressure, so patients with low blood pressure or those taking diuretics should exercise caution.
During treatment, there may be a higher likelihood of genital and urinary tract infections, and if signs of infection manifest, immediate treatment is required.
The metformin component may lower vitamin B12 levels, so regular vitamin B12 testing is recommended during long-term use.
The risk of severe side effects may increase if this medication is taken with alcohol, so excessive drinking should be avoided during treatment.
Temporary discontinuation of this medication is necessary prior to surgery or imaging tests involving iodine contrast agents, and it should be resumed only after kidney function is confirmed to be normal post-surgery.
It is safer for women who are pregnant or may become pregnant, or are breastfeeding to avoid using this medication.
Elderly patients are at increased risk for reduced kidney function and decreased fluid volume, thus requiring dose adjustments and regular monitoring.
In case of overdose, contact a medical facility immediately for appropriate treatment, and metformin can be removed by dialysis.
This medication does not significantly affect driving or operating machinery, but caution is advised as dizziness may occur.
Lastly, keep this medication out of the reach of children, and store it in its original container to prevent misuse or quality degradation.
Side effects
Severe lactic acidosis
severe hypoglycemia
vulvitis
balanitis
genital infection
urinary tract infection
fungal infection
hypoglycemia
decreased fluid volume
thirst
Show 86 moreCollapse
diabetic ketoacidosis
dizziness
constipation
dry mouth
low back pain
dysuria
polyuria
nocturia
vulvar pruritus
genital pruritus
increased hematocrit
decreased renal creatinine clearance
dyslipidemia
increased serum creatinine
increased serum urea
weight loss
ketoacidosis
urinary sepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
decreased vitamin B12
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
tendinitis
chest pain
thermal burn
wrist fracture
gastrointestinal stromal tumor
malignant neoplasm of the lung
uterine fibroids
atrial fibrillation
acute cholecystitis
upper abdominal pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcer
irritable bowel syndrome
salivary gland mass
toothache
headache
facial paralysis
peripheral neuropathy
paresthesia
drowsiness
tremor
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
shingles
pneumonia
rhinitis
increased alanine aminotransferase
increased blood sugar
arthralgia
myalgia
myofascial pain syndrome
osteoarthritis
osteochondrosis
limb pain
periarticular inflammation
tendinitis
trigger finger
weakness
fatigue
peripheral edema
edema
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
skin abrasion
pruritus
palpitations
insomnia
Type 2a hyperlipidemia
sensorineural hearing loss
acute cholecystitis
Not everyone experiences these, and they can vary from person to person.
Storage
This medication must be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 degree Celsius and 30 degrees Celsius. Proper storage will help maintain the efficacy of the medication for a longer period.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.